Schrodinger, Inc.
SDGRSchrödinger, Inc. is an international scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science. Schrödinger's software is used by pharmaceutical companies, biotech, tech, chemicals, energy, aerospace firms, and academic researchers to simulate and model the behavior of molecules at the atomic level. This accelerates the design and develops new drugs and materials more efficiently, reducing the time and cost of bringing them to market.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
SDGR Earnings Report
EPS Est: $-0.60 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
How SDGR's past catalysts played out
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is Schrodinger, Inc.'s next FDA catalyst?→
Schrodinger, Inc.'s (SDGR) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SDGR biotech catalysts?→
Add SDGR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Schrodinger, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.